Not a member? Sign Up

Reasons for Joining

    Address your challenges through knowledge sharing with peers from our global network of specialists.

    Benchmark your business initiatives with the who's who in the field.

    Hear from industry pioneers how to maximize ROI in today's challenging economy.

    And best of all It's FREE!
Sign in using your existing
Pharma IQ account
Username or Email:

Sign Up  |  Already a member? Sign In  |  Visit IQPC.com  
Pharma IQ
Download Brochure

Please complete the information below to complete your download.

Please note: That all fields marked with an asterisk (*) are required.

First Name *
Last Name *
Job Title *
Company Name *
Email Address *
Telephone *
Country *
Where did you hear about us? *

I would like to receive information about sponsorship and exhibition opportunities

Yes, sign me up for the FREE Pharma IQ e-newsletter, including information on FREE Podcasts, Webinars, event discounts and online learning opportunities.



Treating Asthma with Monoclonal Antibody Based Drugs: Past Experience and Future Prospects


Respiratory diseases such as asthma and COPD (chronic obstructive pulmonary disease) are becoming more common, especially in children and the demand for continued advancements in drug discovery has grown significantly in recent years. It is estimated that the commercial drug development market will grow to $23 billion by 2014, with 300 million people in the world suffering from asthma.

Dr. Matthew Catley, Head of Respiratory Pharmacology at UCB, shares his insights on treating asthma with monoclonal antibody based drugs at IQPC's 2nd Asthma & COPD conference in June 2010.

Catley discusses:

  • Examining asthma as a complex inflammatory disease of the lungs involving multiple cells and inflammatory mediators
  • Displaying how mAbs can be targeted to neutralise cytokines, block cell activation or deplete pathogenic cells
  • Exploring past pre-clinical and clinical experience of mAbs for the treatment of asthma
  • Presenting a close examination of the clinical testing of anti IL-5 and TNFa to investigate why these entities have failed in the clinic for the treatment of asthma
  • Identifying lessons learned regarding future antibody based therapies

You Should Check Out:

* = required.

Not a member yet? Sign up
User Name:
Password:
Be the first to leave a comment
Sign in or Sign up to post a comment
Advertisement

Events of Interest
Download Brochure

Please complete the information below to complete your download.

Please note: That all fields marked with an asterisk (*) are required.

First Name *
Last Name *
Job Title *
Company Name *
Email Address *
Telephone *
Country *
Where did you hear about us? *

I would like to receive information about sponsorship and exhibition opportunities

Yes, sign me up for the FREE Pharma IQ e-newsletter, including information on FREE Podcasts, Webinars, event discounts and online learning opportunities.

Advertisement